Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This study encompasses two multicenter, prospective, open-labeled, 2-arm, non-comparative
randomized phase II trials to assess the antitumor activity of bintrafusp alfa in association
with doxorubicin
Phase:
Phase 2
Details
Lead Sponsor:
Institut Bergonié
Collaborator:
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany